TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive NIH to Review Intramural Program: NCI’s Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level March 7, 2014
